PHIO PHARMACEUTICALS ANNOUNCES UPCOMING DATA PRESENTATION AT THE ESMO VIRTUAL CONGRESS 2021
Aug 31, 2021
MARLBOROUGH, Mass., Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL TM) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021.
Details are as follows:
Event: ESMO Virtual Congress 2021
Title: Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors
Authors: Benjamin Cuiffo, et al.
Abstract Number: #4154
Date: September 16-21, 2021